We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 14, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS
METHOD FOR DETERMINING WHETHER A SUBJECT IS AT RISK OF HAVING OR DEVELOPING A CHRONIC KIDNEY DISEASE
METHODS FOR DETERMINING TREATMENT RESPONSE IN PATIENTS INFECTED WITH HCV GENOTYPE 4
COMBINATION THERAPY FOR THE TREATMENT OF CD19+ B-CELL MALIGNANCIES SYMPTOMS COMPRISING AN ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE AND RITUXIMAB
COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME
METHOD FOR PREDICTING THE PRESENCE OF REPRODUCTIVE CELLS IN TESTIS
METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
LOW-DENSITY HOT- OR COLD-ROLLED STEEL, METHOD FOR IMPLEMENTING SAME AND USE THEREOF